Preliminary Study: ENTF Therapy Shows Promise for Stroke Recovery

A preliminary study suggests that electromagnetic network-targeted field (ENTF) therapy, when combined with physical therapy, significantly reduced disability in stroke survivors after 90 days. This finding comes from an analysis of two small clinical trials, which also indicated that ENTF therapy is safe.

Understanding ENTF Therapy

The research, an abstract presented at the American Stroke Association's International Stroke Conference 2026, focused on stimulating specific brain pathways with electromagnetic pulses. The therapy aims to address electrical disorganization in neural networks following a stroke, potentially facilitating the reestablishment of normal network organization.

This therapy demonstrated beneficial effects on organized brain electrical activity and was associated with improved functional recovery for patients.
— Jeffrey L. Saver, M.D., FAHA, lead study author from UCLA

Study Methodology

Researchers combined data from two double-blind, randomized, controlled studies (BQ3 and EMAGINE trials, 2021-2025) involving 124 ischemic stroke survivors. Of these, 65 received ENTF therapy and 59 received sham treatment.

Participants were enrolled approximately 14 days post-stroke with moderate to severe disability (average modified Rankin Scale (mRS) score of 3.9). Both groups underwent 40 to 45 sessions of their respective treatments over 8 to 12 weeks, coupled with physical therapy. Treatments began in the hospital and continued at home using portable kits. Participants' overall disability, motor, and cognitive abilities were assessed after three months.

Key Findings

• The percentage of participants achieving freedom from disability (mRS 0-1) was 22% higher in the ENTF group (33.8%) compared to the sham group (11.9%).
• Measurable improvements were observed in ENTF participants' disability levels across the full range of outcomes, including reduced moderate to severe disability (mRS 3-5) and moderate disability (mRS 2).
• No serious adverse effects were reported among participants who received ENTF therapy.

Future Implications

Dr. Saver highlighted the potential for this therapy to be conducted at home by stroke survivors using a portable kit, addressing a need for more effective rehabilitation therapies.

Joseph P. Broderick, M.D., an American Stroke Association volunteer expert not involved in the study, emphasized the preliminary nature of the results from these small trials and the necessity for larger, balanced trials to confirm the therapy's effectiveness. He also noted the strong demand for new stroke recovery methods.

Stroke remains a leading cause of long-term disability and the fourth leading cause of death in the United States, often impairing movement and daily activities.